Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Notice of Issuance of New Shares in Connection with J-ESOP and RSUs, and Determination of Payment Amount and Other Matters for Prior RSU Awards
Nxera Pharma’s QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
Notice Concerning New Management Structure
Nxera Pharma to Receive $3 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Nxera Pharma Proposes Changes to its Board of Directors
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Notice Concerning Reduction of Executive Compensation
Consolidated Financial Results for the FY2025 (IFRS)
Nxera Pharma to Record Extraordinary Loss on Impairment of Shares of Consolidated Subsidiary (Non-Consolidated)
Variance of Consolidated Results Between the Year Ended 31 December 2025 and the Previous Year
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals